This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Johanna Rossell
CCO at Enzyvant Therapeutics


Johanna Rossell is the Chief Commercial Officer at Enzyant. She leads their commercial enterprise including the U.S. commercialization of RETHYMIC®. She has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams in the US and across several geographic markets around the world. She has led teams to deliver strong business results for companies such as Novartis, Merck, Mallinckrodt, and Biogen, with a robust track record of bringing new products to market and creating integrated pre-and post-launch commercial plans including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare diseases.

Agenda Sessions

  • Lessons Learned from Commercializing a Rare Disease Medicine